Amgen is staring down some major competitive threats to some of its biggest sellers, meaning an acquisition could be in order. And some industry watchers have just the target in mind.
Pfizer and Astellas have their chance to bring Xtandi to prostate cancer patients before their disease has spread. But it’ll be a mano a mano with Johnson & Johnson, whose rival drug Erleada…
Four Democratic senators have published a report rebutting Novartis’ account of the details behind its consulting deal with Michael Cohen, President Donald Trump’s former attorney.
While support from drug companies can be helpful for patients, sometimes support from others struggling with a disease can be even more helpful. So Bayer is offering both.